Supplementary Figure 6: YAP1 knockdown sensitizes cancer cells to RAF-MEK inhibition across multiple tumor types.
From: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
(a,b) Effects of YAP1 knockdown using two independent shRNAs on vemurafenib and trametinib sensitivity in (a) A2058 and (b) WM793 BRAF V600E–mutant melanoma cancer cells. (c,d) Effects of YAP1 knockdown on vemurafenib and trametinib sensitivity in (c) A2058 and (d) WM793 BRAF V600E–mutant melanoma cancer cells (shown is 7-d cell growth assessed by crystal violet staining assays, with quantification of the effects on viability under each condition). (e,f) Effects of YAP1 knockdown using two independent shRNAs on vemurafenib and trametinib sensitivity in (e) HT29 and (f) WiDr BRAF V600E–mutant colon cancer cells. (g,h) Effects of YAP1 knockdown using two independent shRNAs on vemurafenib and trametinib sensitivity in (g) KHM-5M and (h) HTC/C3 BRAF V600E–mutant thyroid cancer cells.
